印度的毒品贩子在安全和质量问题上记得美国的产品, 但印度仍是FDA的顶尖供应商。 Indian drugmakers recall U.S. products over safety and quality issues, but India still leads as a top FDA-compliant supplier.

根据美国食品和药物管理局的说法,印度的药品公司Glenmark,Granules India,Sun Pharma,Zydus和Unichem正在召回美国的各种产品,原因是制造问题,杂质,降解或标签错误. Indian pharmaceutical companies Glenmark, Granules India, Sun Pharma, Zydus, and Unichem are recalling various U.S. products due to manufacturing issues, impurities, degradation, or labeling errors, according to the U.S. FDA. 召回范围从I类,最严重,因为可能造成严重的健康后果,到III类,风险最小. Recalls range from Class I, the most serious, due to potential for serious health consequences, to Class III, with minimal risk. 这些行动是这些公司的美国子公司自愿发起的。 The actions were initiated voluntarily by the companies' U.S. subsidiaries. 尽管有这些回顾,但印度仍然是符合林业发展局要求的药品制造设施最大的非美国来源。 Despite these recalls, India remains the top non-U.S. source of FDA-compliant pharmaceutical manufacturing facilities.